We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

157 hedge funds and large institutions have $949M invested in Karyopharm Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $7.81M | Put options by funds: $4.85M

1% more funds holding

Funds holding: 155 → 157 (+2)

7% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 27

4% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 53

0.45% less ownership

Funds ownership: 6.36% → 5.91% (-0.45%)

28% less capital invested

Capital invested by funds: $1.32B → $949M (-$372M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
157
Holders Change
+2
Holders Change %
+1.29%
% of All Funds
3.17%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
29
Increased
55
Reduced
53
Closed
27
Calls
$7.81M
Puts
$4.85M
Net Calls
+$2.96M
Net Calls Change
-$5.5M

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$17.2M
2
FCM
Frontier Capital Management
Massachusetts
+$14.9M
3
PAI
Palo Alto Investors
California
+$14.1M
4
Citadel Advisors
Citadel Advisors
Florida
+$12.9M
5
BlackRock
BlackRock
New York
+$12.7M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$123M
2
FCM
Farallon Capital Management
California
-$25.3M
3
Goldman Sachs
Goldman Sachs
New York
-$18.5M
4
ACA
Avoro Capital Advisors
New York
-$16.3M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$9.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Candriam SCA
Luxembourg
$7.64M +$4.3M +17,593 +102%
Charles Schwab
27
Charles Schwab
California
$7.53M +$1.18M +4,813 +16%
Morgan Stanley
28
Morgan Stanley
New York
$6.36M +$4.18M +17,078 +143%
Macquarie Group
29
Macquarie Group
Australia
$5.57M – – –
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$5.11M +$5.7M +23,315 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$5.06M +$432K +1,767 +8%
JP Morgan Chase
32
JP Morgan Chase
New York
$4.65M +$780K +3,187 +18%
GIM
33
Granahan Investment Management
Massachusetts
$3.91M -$2.78M -11,359 -39%
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$3.37M -$5.27M -21,565 -58%
CS
35
Credit Suisse
Switzerland
$3.31M -$127K -520 -3%
UBS Group
36
UBS Group
Switzerland
$2.97M +$1.13M +4,620 +52%
Allianz Asset Management
37
Allianz Asset Management
Germany
$2.84M -$77K -315 -2%
JGC
38
J. Goldman & Co
New York
$2.66M +$1.32M +5,377 +80%
Bank of America
39
Bank of America
North Carolina
$2.63M +$500K +2,043 +21%
Wells Fargo
40
Wells Fargo
California
$2.61M -$29.1K -119 -1%
Fidelity Investments
41
Fidelity Investments
Massachusetts
$2.58M -$8.13M -33,226 -74%
IHAM
42
Integral Health Asset Management
New York
$2.56M +$1.63M +6,667 +133%
PFC
43
Phocas Financial Corp
California
$2.48M +$2.76M +11,302 New
BC
44
Birchview Capital
Vermont
$2.45M – – –
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$2.33M +$39.9K +163 +2%
Squarepoint
46
Squarepoint
New York
$2.31M +$1.91M +7,811 +283%
LCM
47
Laurion Capital Management
New York
$2.19M +$2.44M +9,983 New
Rafferty Asset Management
48
Rafferty Asset Management
New York
$2.04M +$1.35M +5,503 +144%
MOACM
49
Mutual of America Capital Management
New York
$2.02M -$385K -1,576 -15%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$1.97M +$585K +2,393 +36%
1
2
3 4 5

KPTI Hedge Fund Activity: Q3 2020 in Review

157 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2020, worth a combined $949M — down 28% from $1.32B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new KPTI positions and 27 closed out — a net gain of 2 holders — while 55 added to existing stakes and 53 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $17.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $123M sold.

  • 157 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2020, up from 155 in Q2 2020.
  • Funds reported $949M of Karyopharm Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
  • 29 funds opened new Karyopharm Therapeutics positions in Q3 2020 and 27 closed out, a net change of +2 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2020 was Two Sigma Investments, an estimated $17.2M added.
  • The largest Karyopharm Therapeutics seller in Q3 2020 was Consonance Capital Management, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2020.